Royal Bank of Canada’s Pacer BioThreat Strategy ETF VIRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-2,729
| Closed | -$109K | – | 7424 |
|
|
2024
Q3 | $109K | Buy |
2,729
+141
| +5% | +$5.38K | ﹤0.01% | 5289 |
|
|
2024
Q2 | $94K | Buy |
2,588
+1,619
| +167% | +$57.7K | ﹤0.01% | 5308 |
|
|
2024
Q1 | $35K | Buy |
+969
| New | +$33.3K | ﹤0.01% | 5690 |
|
|
2023
Q4 | – | Sell |
-22,059
| Closed | -$658K | – | 7712 |
|
|
2023
Q3 | $658K | Buy |
22,059
+4,312
| +24% | +$135K | ﹤0.01% | 3805 |
|
|
2023
Q2 | $554K | Buy |
17,747
+8,500
| +92% | +$253K | ﹤0.01% | 3872 |
|
|
2023
Q1 | $271K | Buy |
9,247
+6,646
| +256% | +$191K | ﹤0.01% | 4375 |
|
|
2022
Q4 | $73K | Sell |
2,601
-11,119
| -81% | -$308K | ﹤0.01% | 5675 |
|
|
2022
Q3 | $346K | Sell |
13,720
-13,030
| -49% | -$358K | ﹤0.01% | 4324 |
|
|
2022
Q2 | $712K | Buy |
26,750
+18,577
| +227% | +$529K | ﹤0.01% | 3785 |
|
|
2022
Q1 | $253K | Sell |
8,173
-14,173
| -63% | -$441K | ﹤0.01% | 4875 |
|
|
2021
Q4 | $778K | Buy |
22,346
+20,202
| +942% | +$687K | ﹤0.01% | 4068 |
|
|
2021
Q3 | $70K | Sell |
2,144
-3,385
| -61% | -$113K | ﹤0.01% | 5959 |
|
|
2021
Q2 | $176K | Sell |
5,529
-41,281
| -88% | -$1.25M | ﹤0.01% | 5186 |
|
|
2021
Q1 | $1.36M | Buy |
46,810
+18,276
| +64% | +$529K | ﹤0.01% | 3325 |
|
|
2020
Q4 | $797K | Sell |
28,534
-2,688
| -9% | -$75.6K | ﹤0.01% | 3706 |
|
|
2020
Q3 | $869K | Buy |
31,222
+30,544
| +4,505% | +$823K | ﹤0.01% | 3382 |
|
|
2020
Q2 | $17K | Buy |
+678
| New | +$16.7K | ﹤0.01% | 5662 |
|
Royal Bank of Canada's VIRS Position: Q4 2024 in Review
Royal Bank of Canada sold out of Pacer BioThreat Strategy ETF (VIRS) in Q4 2024, closing a stake of 2,729 shares — an estimated $109K sold.
Royal Bank of Canada first reported a position in VIRS in Q2 2020 and held it in 17 quarters. The position peaked at $1.36M in Q1 2021. 0 funds tracked by Wall St. Rank hold VIRS as of Q4 2024.
- Royal Bank of Canada reported no remaining Pacer BioThreat Strategy ETF position as of Q4 2024 after selling out during the quarter.
- Royal Bank of Canada sold 2,729 Pacer BioThreat Strategy ETF shares in Q4 2024, an estimated $109K.
- Royal Bank of Canada first reported a position in Pacer BioThreat Strategy ETF in Q2 2020 and held it in 17 quarters.
- Royal Bank of Canada's Pacer BioThreat Strategy ETF position peaked at $1.36M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Pacer BioThreat Strategy ETF as of Q4 2024.
Based on Royal Bank of Canada's 13F filing for Q4 2024, filed 14 Feb 2025.